Grupo IMO

Grupo IMO (Instituto Madrileño de Oncología) is a prominent Spanish healthcare organization dedicated to the diagnosis and treatment of cancer, with a specialized focus on radiotherapy and radiosurgery. Established in 1988, the group has been a pioneer in introducing advanced oncological technologies in Spain, such as CyberKnife and TomoTherapy. Following its acquisition by GenesisCare in 2016, and subsequently by Sanitas (part of the Bupa Group) in 2024, the group continues to operate a network of specialized centers providing multidisciplinary care. Their services encompass medical oncology, brachytherapy, and advanced imaging, supported by a commitment to clinical research and personalized patient care. The group is recognized for its high clinical standards and its role in advancing cancer treatment protocols within the Spanish private health sector.